Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Wilke

Showing results (51-60 of 57) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 57 results.
The American Journal of Pathology|May 18, 1999
Distinct CXC chemokines mediate tumorigenicity of prostate cancer cellsB B Moore, D A Arenberg, K Stoy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2020
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerH S Rugo, F André, T Yamashita, et al.
BMC Cancer|December 18, 2015
Partial PTEN deletion is linked to poor prognosis in breast cancerP Lebok, V Kopperschmidt, M Kluth, et al.
Cancer Biology & Therapy|May 12, 2015
8p deletion is strongly linked to poor prognosis in breast cancerP Lebok, A Mittenzwei, M Kluth, et al.
Hemasphere|August 18, 2025
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working PartyPhilipp Berning, Maud Ngoya, Won Seog Kim, et al.
Cancer Cell|March 4, 2022
The proteogenomic subtypes of acute myeloid leukemiaAshok Kumar Jayavelu, Sebastian Wolf, Florian Buettner, et al.
Blood|October 8, 2021
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphomaAnne C Wilke, Carmen Doebele, Alena Zindel, et al.
Pageof 6

Showing results (51-60 of 57) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 57 results.
The American Journal of Pathology|May 18, 1999
Distinct CXC chemokines mediate tumorigenicity of prostate cancer cellsB B Moore, D A Arenberg, K Stoy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2020
Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancerH S Rugo, F André, T Yamashita, et al.
BMC Cancer|December 18, 2015
Partial PTEN deletion is linked to poor prognosis in breast cancerP Lebok, V Kopperschmidt, M Kluth, et al.
Cancer Biology & Therapy|May 12, 2015
8p deletion is strongly linked to poor prognosis in breast cancerP Lebok, A Mittenzwei, M Kluth, et al.
Hemasphere|August 18, 2025
Autologous stem cell transplantation in NK/T-cell lymphoma: Prognostic impact of EBV-DNA in a multinational cohort-A study by the EBMT Lymphoma Working PartyPhilipp Berning, Maud Ngoya, Won Seog Kim, et al.
Cancer Cell|March 4, 2022
The proteogenomic subtypes of acute myeloid leukemiaAshok Kumar Jayavelu, Sebastian Wolf, Florian Buettner, et al.
Blood|October 8, 2021
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphomaAnne C Wilke, Carmen Doebele, Alena Zindel, et al.
Pageof 6